A pilot study on the safety and efficacy of neoadjuvant chemo‑adoptive immunotherapy for locally advanced rectal cancer-Reference-Cited by-同舟云学术

A pilot study on the safety and efficacy of neoadjuvant chemo‑adoptive immunotherapy for locally advanced rectal cancer

Published:2024-01-15 Issue:3 Volume:27 Page:
ISSN:1792-1074
Container-title:Oncology Letters
language:
Short-container-title:Oncol Lett

Author:

Okazawa Yu¹,Kamigaki Takashi²,Sugimoto Kiichi¹,Yamada Takeshi³,Yoshida Yoichiro⁴,Okada Sachiko²,Ibe Hiroshi²,Oguma Eri²,Iwai Takuma³,Matsuda Akihisa³,Yamada Teppei⁴,Hasegawa Suguru⁴,Goto Shigenori²,Takimoto Rishu²,Sakamoto Kazuhiro¹

Affiliation:

1. Department of Coloproctological Surgery, Faculty of Medicine, Juntendo University, Tokyo 113‑8421, Japan

2. Department of Next‑Generation Cell and Immune Therapy, Faculty of Medicine, Juntendo University, Tokyo 113‑8421, Japan

3. Department of Gastrointestinal and Hepato‑Biliary‑Pancreatic Surgery, Nippon Medical School, Tokyo 113‑8603, Japan

4. Department of Gastroenterological Surgery, Faculty of Medicine, Fukuoka University, Fukuoka 814‑0180, Japan

Publisher

Spandidos Publications

Reference33 articles.

1. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology;Benson;J Natl Compr Canc Netw,2018

2. The TME trial after a median follow-up of 6 years: Increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma;Peeters;Ann Surg,2007

3. Swedish rectal cancer trial: Long lasting benefits from radiotherapy on survival and local recurrence rate;Folkesson;J Clin Oncol,2005

4. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years;Sauer;J Clin Oncol,2012

5. Neoadjuvant CAPOX and bevacizumab alone for locally advanced rectal cancer: Long-term results from the N-SOG 03 trial;Tomida;Int J Clin Oncol,2019